Literature DB >> 1111741

The HL-A system in asbestos workers.

J A Merchant, P T Klouda, C A Soutar, W R Parkes, S D Lawler, M Turner-Warwick.   

Abstract

In a study of the HL-A system in 56 selected asbestos workers referred to the Pneumoconiosis Medical Panel with definite or suspected asbestosis, the W 27 antigen was found more often than among a control population. Six of the 10 asbestos workers with the W 27 antigen had definite radiographic evidence of asbestosis compared to 13 out of 46 without the W 27 antigen. These observations, if confirmed, suggest that the W 27 antigen may provide a useful marker of an enhanced susceptibility to the tissue-damaging effects of asbestos dust.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1111741      PMCID: PMC1672170          DOI: 10.1136/bmj.1.5951.189

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  Circulating antinuclear antibody and rheumatoid factor in coal pneumoconiosis.

Authors:  C A Soutar; M Turner-Warwick; W R Parkes
Journal:  Br Med J       Date:  1974-07-20

2.  Circulating antinuclear and rheumatoid factors in coal miners. A prevalence study in Pennsylvania and West Virginia.

Authors:  M Lippmann; H L Eckert; N Hahon; W K Morgan
Journal:  Ann Intern Med       Date:  1973-12       Impact factor: 25.391

3.  Acute anterior uveitis and HL-A 27.

Authors:  D A Brewerton; M Caffrey; A Nicholls; D Walters; D C James
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

4.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

5.  Circulating rheumatoid and antinuclear factors in asbestos workers.

Authors:  M Turner-Warwick; W R Parkes
Journal:  Br Med J       Date:  1970-08-29

6.  Human lymphocyte antigen association in ankylosing spondylitis.

Authors:  M F Caffrey; D C James
Journal:  Nature       Date:  1973-03-09       Impact factor: 49.962

7.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

8.  A new HL-A antigen: TY.

Authors:  K Gelsthorpe; R W Doughty
Journal:  Tissue Antigens       Date:  1973

9.  Evidence of dose-response relation in pneumoconiosis. 1.

Authors:  C E Rossiter
Journal:  Trans Soc Occup Med       Date:  1972-07

10.  Rheumatoid factor in serum of individuals exposed to asbestos.

Authors:  B Pernis; E C Vigliani; I J Selikoff
Journal:  Ann N Y Acad Sci       Date:  1965-12-31       Impact factor: 5.691

  10 in total
  7 in total

1.  Asbestos-related lung disease.

Authors: 
Journal:  West J Med       Date:  1979-09

2.  Elevated binding activity of CD8+ cells with phytohaemagglutinin by asbestos fibre in vitro.

Authors:  K Kinugawa; F Hyodoh; A Andoh; A Ueki; H Tanaka; Y Mochizuki
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

3.  Immunogenetic factors as determinants of asbestosis.

Authors:  R Bégin; H Ménard; F Décarie; A St-Sauveur
Journal:  Lung       Date:  1987       Impact factor: 2.584

4.  Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma.

Authors:  P L Haslam; A Lukoszek; J A Merchant; M Turner-Warwick
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  The histocompatibility antigen in asbestos related disease.

Authors:  N Al Jarad; S Uthayakumar; E J Buckland; T S Green; J Ord; A C Newland; R M Rudd
Journal:  Br J Ind Med       Date:  1992-12

Review 6.  The ramifications of HLA-B27.

Authors:  Nicholas J Sheehan
Journal:  J R Soc Med       Date:  2004-01       Impact factor: 18.000

Review 7.  Trends and perspectives of the biological prophylaxis of silicosis.

Authors:  B A Katsnelson; E V Polzik; K I Morosova; L I Privalova; N S Kislitsina; V S Kasantsev
Journal:  Environ Health Perspect       Date:  1989-07       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.